{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:36:44Z","timestamp":1784547404669,"version":"3.55.0"},"reference-count":97,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,5,30]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Evidence-based recommendations have been established for treatment of chronic myeloid leukemia (CML) in adults treated with tyrosine kinase inhibitors (TKIs), but the rarity of this leukemia in children and adolescents makes it challenging to develop similar recommendations in pediatrics. In addition to imatinib, which was approved for pediatric CML in 2003, the second-generation TKIs dasatinib and nilotinib were recently approved for use in children, expanding the therapeutic options and pushing allogeneic stem cell transplantation to a third-line treatment of most pediatric cases. Yet, without sufficient data on efficacy and safety specific to pediatric patients, the selection of a TKI continues to rely on clinical experience in adults. Here, we present 4 case scenarios highlighting common yet challenging issues encountered in the treatment of pediatric CML (suboptimal response, poor treatment adherence, growth retardation, and presentation in advanced phases). Limited experience with very young children, the transition of teenagers to adult medicine, and the goal of achieving treatment-free remission for this rare leukemia are additional significant obstacles that require further clinical investigation through international collaboration.<\/jats:p>","DOI":"10.1182\/blood.2018882233","type":"journal-article","created":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T02:05:10Z","timestamp":1553738710000},"page":"2374-2384","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":105,"title":["How I treat chronic myeloid leukemia in children and adolescents"],"prefix":"10.1182","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0199-054X","authenticated-orcid":false,"given":"Nobuko","family":"Hijiya","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Columbia University Medical Center, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9522-8838","authenticated-orcid":false,"given":"Meinolf","family":"Suttorp","sequence":"additional","affiliation":[{"name":"Medical Faculty, Pediatric Hematology and Oncology, Technical University Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2020021109201416500_B1","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/blood-2015-06-648667","article-title":"Pediatric chronic myeloid leukemia is a unique disease that requires a different approach","volume":"127","author":"Hijiya","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2020021109201416500_B2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.pcl.2014.09.008","article-title":"Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions","volume":"62","author":"Hijiya","year":"2015","journal-title":"Pediatr Clin North Am"},{"issue":"1","key":"2020021109201416500_B3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/annonc\/mdu490","article-title":"Differences among young adults, adults and elderly chronic myeloid leukemia patients","volume":"26","author":"Castagnetti","year":"2015","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"2020021109201416500_B4","first-page":"316","article-title":"advanced phases at diagnosis of childhood chronic myeloid leukemia: the experience of the International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped Study) [abstract]","volume":"130","author":"Millot","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2020021109201416500_B5","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/gcc.21989","article-title":"Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia","volume":"51","author":"Krumbholz","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"issue":"9","key":"2020021109201416500_B6","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1038\/s41375-018-0157-2","article-title":"Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia","volume":"32","author":"Ernst","year":"2018","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2020021109201416500_B7","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1182\/blood-2018-99-119974","article-title":"Comparison of the transcriptomic signature of pediatric vs. adult CML and normal bone marrow stem cells [abstract]","volume":"132","author":"Chae","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2020021109201416500_B8","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1182\/blood.V72.1.294.294","article-title":"Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia","volume":"72","author":"Sokal","year":"1988","journal-title":"Blood"},{"issue":"3","key":"2020021109201416500_B9","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2020021109201416500_B10","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"2020021109201416500_B11","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00277-015-2367-2","article-title":"Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients?","volume":"94","author":"Gurrea Salas","year":"2015","journal-title":"Ann Hematol"},{"issue":"10","key":"2020021109201416500_B12","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.3324\/haematol.2017.170035","article-title":"Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents","volume":"102","author":"Millot","year":"2017","journal-title":"Haematologica"},{"issue":"24","key":"2020021109201416500_B13","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020021109201416500_B14","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/s41375-018-0179-9","article-title":"Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial","volume":"32","author":"Suttorp","year":"2018","journal-title":"Leukemia"},{"issue":"20","key":"2020021109201416500_B15","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.2010.32.7114","article-title":"Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial","volume":"29","author":"Millot","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020021109201416500_B16","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/pbc.23031","article-title":"Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children\u2019s Oncology Group","volume":"57","author":"Champagne","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"13","key":"2020021109201416500_B17","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1200\/JCO.2017.75.9597","article-title":"Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: results from a phase II trial","volume":"36","author":"Gore","year":"2018","journal-title":"J Clin Oncol"},{"issue":"S3","key":"2020021109201416500_B18","first-page":"S22","article-title":"Efficacy and safety of nilotinib in pediatric patients with Philadelphia chromosome\u2013positive (PH+) chronic myeloid leukemia (CML): results from a phase 2 trial [abstract]","volume":"64","author":"Hijiya","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2020021109201416500_B19","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jpeds.2011.03.046","article-title":"Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia","volume":"159","author":"Shima","year":"2011","journal-title":"J Pediatr"},{"issue":"3","key":"2020021109201416500_B20","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/pbc.23389","article-title":"Imatinib has adverse effect on growth in children with chronic myeloid leukemia","volume":"59","author":"Bansal","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"2020021109201416500_B21","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/pbc.26028","article-title":"Recognizing endocrinopathies associated with tyrosine kinase inhibitor therapy in children with chronic myelogenous leukemia","volume":"63","author":"Samis","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"2020021109201416500_B22","doi-asserted-by":"crossref","first-page":"e26703","DOI":"10.1002\/pbc.26703","article-title":"The complexity of growth failure in children receiving tyrosine kinase inhibitor therapy for chronic myelogenous leukemia","volume":"64","author":"Samis","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"18","key":"2020021109201416500_B23","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1016\/j.ejca.2014.10.007","article-title":"Growth deceleration in children treated with imatinib for chronic myeloid leukaemia","volume":"50","author":"Millot","year":"2014","journal-title":"Eur J Cancer"},{"issue":"6","key":"2020021109201416500_B24","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"key":"2020021109201416500_B25","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1182\/asheducation-2017.1.102","article-title":"Treatment-free remission in CML: who, how, and why?","volume":"2017","author":"Mahon","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8","key":"2020021109201416500_B26","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/leu.2016.115","article-title":"The concept of treatment-free remission in chronic myeloid leukemia","volume":"30","author":"Sau\u00dfele","year":"2016","journal-title":"Leukemia"},{"issue":"2","key":"2020021109201416500_B27","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/bjh.13103","article-title":"Treatment-free remission after imatinib discontinuation is possible in paediatric patients with chronic myeloid leukaemia","volume":"168","author":"Giona","year":"2015","journal-title":"Br J Haematol"},{"issue":"1","key":"2020021109201416500_B28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/bjh.12977","article-title":"Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years","volume":"167","author":"de la Fuente","year":"2014","journal-title":"Br J Haematol"},{"issue":"2","key":"2020021109201416500_B29","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s11899-012-0113-6","article-title":"Management of chronic myeloid leukemia in childhood","volume":"7","author":"Suttorp","year":"2012","journal-title":"Curr Hematol Malig Rep"},{"issue":"S1","key":"2020021109201416500_B30","first-page":"S34","article-title":"Nilotinib in pediatric patients with philadelphia chromosome-positive (PH+) chronic myeloid leukemia (CML) or PH+ acute lymphoblastic leukemia (ALL): a pharmacokinetic study [abstract]","volume":"64","author":"Hijiya","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"19","key":"2020021109201416500_B31","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2012.46.8280","article-title":"Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium","volume":"31","author":"Zwaan","year":"2013","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020021109201416500_B32","doi-asserted-by":"crossref","first-page":"e27431","DOI":"10.1002\/pbc.27431","article-title":"Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients","volume":"65","author":"Suttorp","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"2020021109201416500_B33","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/jnci\/djw003","article-title":"Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States","volume":"108","author":"Padula","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"2020021109201416500_B34","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"20","key":"2020021109201416500_B35","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the Dasatinib Versus Imatinib Study in Treatment-Na\u00efve Chronic Myeloid Leukemia Patients Trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020021109201416500_B36","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE Trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020021109201416500_B37","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2013.69","article-title":"Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"2020021109201416500_B38","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","article-title":"Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis","volume":"2","author":"Douxfils","year":"2016","journal-title":"JAMA Oncol"},{"issue":"10","key":"2020021109201416500_B39","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up [published correction appears in Leukemia. 2012;26:2302]","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"issue":"24","key":"2020021109201416500_B40","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1182\/bloodadvances.2018018614","article-title":"Imatinib is still recommended for frontline therapy for CML","volume":"2","author":"Hantel","year":"2018","journal-title":"Blood Adv"},{"issue":"24","key":"2020021109201416500_B41","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1182\/bloodadvances.2018018655","article-title":"A second-generation TKI should always be used as initial therapy for CML","volume":"2","author":"Cortes","year":"2018","journal-title":"Blood Adv"},{"key":"2020021109201416500_B42","author":"NCCN Clinical Practice Guidelines in Oncology"},{"issue":"9","key":"2020021109201416500_B43","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","article-title":"Chronic MYELOID LEUKEMIA, VERSion 1.2019, NCCN clinical practice guidelines in oncology","volume":"16","author":"Radich","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"suppl 2","key":"2020021109201416500_B44","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1007\/s00277-015-2322-2","article-title":"A review of the European LeukemiaNet recommendations for the management of CML","volume":"94","author":"Baccarani","year":"2015","journal-title":"Ann Hematol"},{"issue":"4","key":"2020021109201416500_B45","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","article-title":"Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors","volume":"31","author":"Patel","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"issue":"5","key":"2020021109201416500_B46","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2020021109201416500_B47","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/pbc.24521","article-title":"Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase","volume":"61","author":"Millot","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"27","key":"2020021109201416500_B48","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","article-title":"Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?","volume":"114","author":"Branford","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2020021109201416500_B49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/ped.13437","article-title":"Response to ponatinib before hematopoietic stem cell transplantation in a child with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"60","author":"Yamamoto","year":"2018","journal-title":"Pediatr Int (Roma)"},{"issue":"11","key":"2020021109201416500_B50","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1002\/pbc.25551","article-title":"Treatment of an adolescent with chronic myeloid leukemia and the T315I mutation with ponatinib","volume":"62","author":"Nickel","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2020021109201416500_B51","first-page":"793","article-title":"Promoting medication adherence in children","volume":"74","author":"Gardiner","year":"2006","journal-title":"Am Fam Physician"},{"issue":"5","key":"2020021109201416500_B52","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3109\/08880018.2012.693150","article-title":"Adherence to leukemia maintenance therapy: a comparative study among children, adolescents, and adults","volume":"29","author":"Mancini","year":"2012","journal-title":"Pediatr Hematol Oncol"},{"issue":"7","key":"2020021109201416500_B53","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00432-017-2372-z","article-title":"Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries","volume":"143","author":"Geissler","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"2020021109201416500_B54","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/00004479-200101000-00004","article-title":"Management of chronic pediatric diseases with interactive health games: theory and research findings","volume":"24","author":"Lieberman","year":"2001","journal-title":"J Ambul Care Manage"},{"issue":"14","key":"2020021109201416500_B55","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020021109201416500_B56","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ajh.22019","article-title":"Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia","volume":"86","author":"Ganesan","year":"2011","journal-title":"Am J Hematol"},{"issue":"2","key":"2020021109201416500_B57","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1093\/jpepsy\/jsw039","article-title":"Measuring medication adherence in pediatric cancer: an approach to validation","volume":"42","author":"Rohan","year":"2017","journal-title":"J Pediatr Psychol"},{"issue":"S2 Suppl 2","key":"2020021109201416500_B58","doi-asserted-by":"crossref","first-page":"S227","DOI":"10.1007\/s00277-015-2327-x","article-title":"Response-related predictors of survival in CML","volume":"94","author":"Hanfstein","year":"2015","journal-title":"Ann Hematol"},{"issue":"9","key":"2020021109201416500_B59","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00277-012-1458-6","article-title":"Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group","volume":"91","author":"Efficace","year":"2012","journal-title":"Ann Hematol"},{"issue":"4","key":"2020021109201416500_B60","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3324\/haematol.2013.093724","article-title":"Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia","volume":"99","author":"Efficace","year":"2014","journal-title":"Haematologica"},{"issue":"14","key":"2020021109201416500_B61","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1002\/cncr.30648","article-title":"Cost-related medication nonadherence among adolescent and young adult cancer survivors","volume":"123","author":"Kaul","year":"2017","journal-title":"Cancer"},{"issue":"6","key":"2020021109201416500_B62","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1200\/JOP.2016.019737","article-title":"Journey of generic imatinib: a case study in oncology drug pricing","volume":"13","author":"Chen","year":"2017","journal-title":"J Oncol Pract"},{"issue":"3","key":"2020021109201416500_B63","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1055\/s-0033-1343483","article-title":"TK inhibitor treatment disrupts growth hormone axis: clinical observations in children with CML and experimental data from a juvenile animal model","volume":"225","author":"Ulmer","year":"2013","journal-title":"Klin Padiatr"},{"issue":"12","key":"2020021109201416500_B64","doi-asserted-by":"crossref","first-page":"CR721","DOI":"10.12659\/MSM.883599","article-title":"Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment","volume":"18","author":"Jaeger","year":"2012","journal-title":"Med Sci Monit"},{"issue":"1","key":"2020021109201416500_B65","first-page":"1382","article-title":"Off-target effect of imatinib and nilotinib on human vitamin D3 metabolism","volume":"17","author":"Kroschwald","year":"2018","journal-title":"Mol Med Rep"},{"issue":"7","key":"2020021109201416500_B66","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1002\/pbc.24397","article-title":"Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH\/IGF-1 axis","volume":"60","author":"Narayanan","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"2020021109201416500_B67","doi-asserted-by":"crossref","first-page":"e0131192","DOI":"10.1371\/journal.pone.0131192","article-title":"Impact of long-term exposure to the tyrosine kinase inhibitor imatinib on the skeleton of growing rats","volume":"10","author":"Tauer","year":"2015","journal-title":"PLoS One"},{"issue":"21","key":"2020021109201416500_B68","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1182\/blood.V124.21.522.522","article-title":"Impairment of longitudinal growth by tyrosine kinase inhibitor (TKI) treatment - data from a large pediatric cohort with chronic myeloid leukemia (CML) [abstract]","volume":"124","author":"Tauer","year":"2014","journal-title":"Blood"},{"issue":"22","key":"2020021109201416500_B69","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1182\/blood.V128.22.1884.1884","article-title":"Impact of long-term tyrosine kinase inhibitor exposure on spermatogenesis in juvenile rats [abstract]","volume":"128","author":"Girke","year":"2016","journal-title":"Blood"},{"key":"2020021109201416500_B70","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1182\/asheducation-2017.1.110","article-title":"Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy","volume":"2017","author":"Barber","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8","key":"2020021109201416500_B71","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"issue":"3","key":"2020021109201416500_B72","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020021109201416500_B73","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2020021109201416500_B74","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020021109201416500_B75","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/leu.2017.63","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study","volume":"31","author":"Hochhaus","year":"2017","journal-title":"Leukemia"},{"issue":"12","key":"2020021109201416500_B76","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial","volume":"2","author":"Imagawa","year":"2015","journal-title":"Lancet Haematol"},{"issue":"1","key":"2020021109201416500_B77","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2020021109201416500_B78","doi-asserted-by":"crossref","first-page":"E480","DOI":"10.1002\/ajh.24495","article-title":"Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia","volume":"91","author":"Claudiani","year":"2016","journal-title":"Am J Hematol"},{"issue":"8","key":"2020021109201416500_B79","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/MPH.0000000000000636","article-title":"Outcomes following bone marrow transplantation in children with accelerated phase or blast crisis chronic myelogenous leukemia in the era of tyrosine kinase inhibitors","volume":"38","author":"Shulman","year":"2016","journal-title":"J Pediatr Hematol Oncol"},{"issue":"3","key":"2020021109201416500_B80","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.beha.2016.10.005","article-title":"Management of CML-blast crisis","volume":"29","author":"Hehlmann","year":"2016","journal-title":"Best Pract Res Clin Haematol"},{"issue":"22","key":"2020021109201416500_B81","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/cncr.30864","article-title":"Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"},{"issue":"4","key":"2020021109201416500_B82","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood-2012-03-380147","article-title":"How I treat CML blast crisis","volume":"120","author":"Hehlmann","year":"2012","journal-title":"Blood"},{"issue":"S2 Suppl 2","key":"2020021109201416500_B83","doi-asserted-by":"crossref","first-page":"S159","DOI":"10.1007\/s00277-015-2324-0","article-title":"Management of chronic myeloid leukemia in blast crisis","volume":"94","author":"Sau\u00dfele","year":"2015","journal-title":"Ann Hematol"},{"issue":"6","key":"2020021109201416500_B84","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"23","key":"2020021109201416500_B85","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1182\/blood.V126.23.2789.2789","article-title":"Description and management of accelerated phase and blast crisis in 21 CML pediatric patients [abstract]","volume":"126","author":"Meyran","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2020021109201416500_B86","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.bbmt.2016.02.015","article-title":"Outcomes of allogeneic hematopoietic cell transplantation in children and young adults with chronic myeloid leukemia: a CIBMTR cohort analysis","volume":"22","author":"Chaudhury","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2020021109201416500_B87","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0029-1239529","article-title":"Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: results from the prospective trial CML-paed I","volume":"221","author":"Suttorp","year":"2009","journal-title":"Klin Padiatr"},{"issue":"9","key":"2020021109201416500_B88","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/ajh.24423","article-title":"Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034","volume":"91","author":"Shah","year":"2016","journal-title":"Am J Hematol"},{"issue":"12","key":"2020021109201416500_B89","doi-asserted-by":"crossref","first-page":"e27368","DOI":"10.1002\/pbc.27368","article-title":"Sequential use of second-generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid leukemia: a report from the Japanese pediatric leukemia\/lymphoma study group","volume":"65","author":"Kurosawa","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2020021109201416500_B90","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11899-016-0304-7","article-title":"accelerated phase cml: Outcomes in Newly Diagnosed vs. Progression From Chronic Phase","volume":"11","author":"mukherjee","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"issue":"8","key":"2020021109201416500_B91","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.bbmt.2015.04.005","article-title":"Allogeneic hematopoietic stem cell transplantation is an effective salvage therapy for patients with chronic myeloid leukemia presenting with advanced disease or failing treatment with tyrosine kinase inhibitors","volume":"21","author":"Nair","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2020021109201416500_B92","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.leukres.2009.04.036","article-title":"Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib","volume":"34","author":"Breccia","year":"2010","journal-title":"Leuk Res"},{"issue":"11","key":"2020021109201416500_B93","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s00277-015-2457-1","article-title":"Pretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcome","volume":"94","author":"Piekarska","year":"2015","journal-title":"Ann Hematol"},{"issue":"9","key":"2020021109201416500_B94","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/ajh.24793","article-title":"Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia","volume":"92","author":"Kondo","year":"2017","journal-title":"Am J Hematol"},{"issue":"6","key":"2020021109201416500_B95","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.bbmt.2016.03.012","article-title":"Allogeneic stem cell transplantation for patients with T315I BCR-ABL mutated chronic myeloid leukemia","volume":"22","author":"Xu","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"15","key":"2020021109201416500_B96","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1002\/cncr.30558","article-title":"Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation","volume":"123","author":"Nicolini","year":"2017","journal-title":"Cancer"},{"issue":"7","key":"2020021109201416500_B97","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study","volume":"129","author":"Rea","year":"2017","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/133\/22\/2374\/1553482\/blood882233.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/133\/22\/2374\/1553482\/blood882233.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T03:48:53Z","timestamp":1607053733000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/133\/22\/2374\/273851\/How-I-treat-chronic-myeloid-leukemia-in-children"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,30]]},"references-count":97,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2019,5,30]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2018882233","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,30]]}}}